Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)
Sino-US biotech Laekna Therapeutics (HKG: 2105) and Qilu Pharmaceutical Co., Ltd. announced today an exclusive...
Qilu Pharmaceutical
Suzhou‑Based InnoBM Partners with Qilu Pharmaceutical on BM601 Metallic Embolic Microsphere
InnoBM Pharmaceuticals Co., Ltd. and Qilu Pharmaceutical Co. have inked a collaboration agreement to commercialize...
Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation
China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...
Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer
China‑based Qilu Pharmaceutical Co., Ltd. announced that it has opened enrollment for its first‑in‑class QLS31905...
Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence
China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....
Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced a licensing agreement with compatriot firm...
Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development
China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....
Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...
United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA
Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...
10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion
The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...
National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs
The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...
Qilu Pharmaceutical’s QL1706 Receives NMPA Conditional Approval for Cervical Cancer Treatment
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its combination drug QL1706, comprising iparomlimab...
Alibaba Health Forges Strategic Partnerships with Viatris and Chinese Pharma Companies for Digital Health Expansion
Alibaba Health Information Technology Ltd (HKG: 0241), the health industry arm of Chinese e-commerce giant...
Qilu Pharmaceutical’s Iruplinalkib Shows Promising Results in Phase II Study for ALK+ NSCLC
Qilu Pharmaceutical, a leading pharmaceutical company based in China, has presented updated results from the...
Qilu Pharmaceutical’s Biosimilar Ranibizumab Receives NMPA Approval, Marking a First in China
Qilu Pharmaceutical, a Chinese pharmaceutical company, has announced that its biosimilar version of Novartis’s blockbuster...
Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
Johnson & Johnson’s Opsumit Faces Generic Competition with Qilu Pharmaceutical’s Entry
Johnson & Johnson (J&J, NYSE: JNJ)’s pulmonary hypertension treatment, Opsumit (macitentan), is set to encounter...
Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...